Princess Margaret Cancer Centre-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2022

  1. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1335-1354

2021

  1. The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

    Journal of Thoracic Oncology, Vol. 16, Núm. 4, pp. 686-696

2020

  1. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee

    Journal of Thoracic Oncology, Vol. 15, Núm. 10, pp. 1599-1610

  2. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

    Journal of Thoracic Oncology, Vol. 15, Núm. 4, pp. 499-519

  3. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee

    Journal of Thoracic Oncology, Vol. 15, Núm. 9, pp. 1409-1424

2019

  1. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 3, pp. 377-407

2017

  1. Programmed death-ligand 1 immunohistochemistry testing: A review of analytical assays and clinical implementation in non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 35, Núm. 34, pp. 3867-3876